About Liquidia
Liquidia is a company based in United States founded in 2004. Liquidia has raised $75.3 million across 12 funding rounds from investors including Gates Foundation, NIST and Canaan. The company has 157 employees as of December 31, 2024. Liquidia has completed 1 acquisition, including Raregen. Liquidia operates in a competitive market with competitors including Sirnaomics, Acorda, Genedit, NanoSyrinx and Ensysce, among others.
- Headquarter United States
- Employees 157 as on 31 Dec, 2024
- Stage Public
-
Sectors
TechnologyHealthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Liquidia Corporation
-
Annual Revenue
$14 M (USD)-19.97as on Dec 31, 2024
-
Net Profit
-$130.39 M (USD)-66.1as on Dec 31, 2024
-
EBITDA
-$119.1 M (USD)-67.26as on Dec 31, 2024
-
Total Equity Funding
$75.3 M (USD)
in 12 rounds
-
Latest Funding Round
$21.7 M (USD), Post-IPO
Apr 13, 2021
-
Investors
Gates Foundation
& 12 more
-
Employee Count
157
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Liquidia
Liquidia is a publicly listed company on the NASDAQ with ticker symbol LQDA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Liquidia
Unlock access to complete
Funding Insights of Liquidia
Liquidia has successfully raised a total of $75.3M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.7 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Liquidia
Liquidia has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Gates Foundation, NIST and Canaan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are directed toward early and late-stage companies.
|
Locked | Locked | Locked | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked |
Investor details for Liquidia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Liquidia
Liquidia has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Raregen.
Investment portfolio details for Liquidia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Strategy planning and investment consulting are provided for healthcare sectors.
|
Locked | Locked | 2018 | Locked |
Complete acquisition details for Liquidia
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Liquidia
Detailed financials for Liquidia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Liquidia Comparisons
Peer comparison for Liquidia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Liquidia
Liquidia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sirnaomics, Acorda, Genedit, NanoSyrinx and Ensysce, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| Locked | Locked | Locked |
Engaged in the development and commercialization of therapies that improve neurological function.
|
|
| Locked | Locked | Locked |
Genetic medicines are delivered using polymer nanoparticle platforms.
|
|
| Locked | Locked | Locked |
Drug delivery systems to cell interiors are developed via nanosyringes.
|
|
| Locked | Locked | Locked |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
Detailed competitors of Liquidia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Liquidia
Complete news archive for Liquidia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Liquidia
Liquidia was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Liquidia is headquartered in United States.
Liquidia is a funded company, having raised a total of $75.3M across 12 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Liquidia is 157.
Annual revenue of Liquidia is $14M as on Dec 31, 2024.
Liquidia Technologies was founded in 2004 in the United States. Engineered particles and films are developed and manufactured for applications in life sciences and materials sciences. Micro- and nanoparticles are created for delivering biological and small molecule therapeutics, as well as for vaccines and inhaled treatments. Nano-patterned optical films are produced for displays, lighting, photovoltaics, and related uses.
Liquidia's top competitors include Sirnaomics, Arcturus Therapeutics and Acorda.
Yes, Liquidia is publicly traded on NASDAQ under the ticker symbol LQDA.
Liquidia has made 1 acquisition, including Raregen.
Liquidia has 13 investors. Key investors include Gates Foundation, NIST, Canaan, Revelation Partners, and Amereus.
The ticker symbol of Liquidia is LQDA on NASDAQ.